Injectable Drugs Market by Molecule Type, Drug Class, Injection Routes, Application

Description

List of Tables

[199 Pages Report] The Injectable Drugs Market size was estimated at USD 563.30 billion in 2023 and expected to reach USD 617.04 billion in 2024, at a CAGR 9.86% to reach USD 1,088.55 billion by 2030.

The injectable drugs market comprises sales and distribution of medications and therapies that are administered through intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection routes. The market caters to various drugs, including antibiotics, insulin, vaccines, and oncology treatments, that are integral in treating multiple diseases and medical conditions. Injectable drugs have diverse applications ranging from emergency care to routine administration of chronic disease medications. They are used in hospitals, clinics, and, increasingly, self-care settings due to advancements in auto-injection devices. Several factors, such as the rising burden of chronic diseases, the growing use of prefilled and self-injectable drugs, and the ongoing practice of steady drug delivery vehicles for cancer treatment, drive the development of the injectable drugs market. However, the market faces limitations and challenges, including high research and development costs, regulatory compliance costs, and complex manufacturing processes under stringent conditions. On the other hand, new opportunities are emerging due to rapid developments and approvals in injectable drugs and strategic alliances among manufacturers for injectable drugs. Moreover, improving drug delivery methods' safety, convenience, and efficacy can lead to increased patient compliance and better outcomes.

KEY MARKET STATISTICS
Base Year [2023]	USD 563.30 billion
Estimated Year [2024]	USD 617.04 billion
Forecast Year [2030]	USD 1,088.55 billion
CAGR (%)	9.86%

Drug Class: Increasing preference for cytokines injectable protein for cell signaling

Blood factors, essential for blood clotting, are injectable agents used to treat and prevent bleeding in individuals with hemophilia and other clotting disorders. They are derived either from human plasma or through recombinant technology. Hemophilia A and B are the most common disorders requiring these treatments. Cytokines are a broad category of injectable proteins critical in cell signaling within the immune system. They include interferons, interleukins, and colony-stimulating factors and are used in treating cancers and autoimmune conditions. Immunoglobulins are essential immune system components commonly used for various immunodeficiency syndromes and autoimmune diseases. These drugs provide necessary antibodies for the immune system to combat pathogens. Insulin is a peptide hormone vital for the regulation of blood glucose levels. It is primarily administered to individuals with diabetes when their body cannot produce sufficient insulin naturally. Monoclonal Antibodies (mAbs) are engineered molecules that imitate the immune system's capacity to fight off harmful pathogens. These drugs have transformed treatment across a spectrum of conditions, including cancer, autoimmune diseases, and infectious diseases. Peptide hormones encompass a variety of injectable hormones other than insulin, such as growth hormone, glucagon-like peptide-1 (GLP-1) agonists for diabetes, and calcitonin. They play various roles, including regulating growth, glucose metabolism, and bone homeostasis.

Application: Growing application of injectable drugs for treating autoimmune diseases

Injectable drugs for autoimmune diseases treat various conditions, including rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Biologics, a subclass of injectable drugs, are often prescribed due to their targeted approach to modulating the immune system. The need-based preference for injectables stems from their quick onset of action and higher efficacy than oral medications. Injectable drugs for cardiovascular diseases aim to manage conditions such as heart failure, arrhythmia, and hypertension. These injections are often critical in emergency settings, providing rapid action where delayed treatment, such as anticoagulants or clotting factors, can be fatal. For infectious diseases, injectable drugs are crucial for antivirals, antibiotics, and antifungals, especially when high blood concentrations are required quickly, or oral administration is not feasible. They are critical in hospital settings for severe or resistant infections. Neurology injectables treat disorders, including Alzheimer's, multiple sclerosis, and migraines. Monoclonal antibodies are significant in this segment for their ability to cross the blood-brain barrier. Oncology injectables include chemotherapy agents, hormonal therapies, and immunotherapies, essential for treating various cancers. The preference for injections comes from the need to achieve high local concentration and to bypass gastrointestinal absorption issues. Injectable drugs for pain management, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred in acute, chronic, and post-operative pain management for their speed and efficacy. In comparing the application segments for injectable drugs, it is apparent that each serves a distinct need in the healthcare sphere. Autoimmune diseases require long-term treatment regimens where injectables offer sustained relief. In contrast, cardiovascular injectable drugs are often emergency-related and demand rapid physiological responses. Infectious disease injectables must be broad-spectrum and rapidly acting to curb infections effectively. Neurology benefits from the targeted delivery achieved by injectables, a distinct advantage given the blood-brain barrier challenge. Injectable oncology drugs offer the benefit of targeted therapy with higher concentrations at the tumor site. Lastly, pain management with injectables provides immediate relief from acute and severe pain, which is often unattainable with oral medications.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a high demand for injectable drugs due to the prevalence of diseases such as diabetes and cancer. Advanced healthcare infrastructure and high per capita healthcare expenditure drive the innovation and adoption of new injection technologies. Drug efficacy, safety profiles, and ease of use influence customer purchasing behavior in these markets. South America's market for injectable drugs is growing steadily due to improving healthcare facilities, increasing economic stability, and governmental support for healthcare reforms in countries such as Brazil, Argentina, and Chile. Europe represents a developing injectable drug market with well-established healthcare systems and favorable reimbursement policies. Eastern European countries are experiencing faster growth rates due to increased accessibility to advanced therapeutics. The Middle East, with countries such as Saudi Arabia and the UAE, shows a promising injectable drugs market due to rising healthcare infrastructure and increasing private sector investments. Africa, on the other hand, is progressively adopting injectable drug therapies but faces challenges related to affordability and access to medicine. The APAC region is emerging as the fastest-growing market for injectable drugs, driven by economic growth, expanding healthcare sectors, and increasing investments in biopharmaceutical research. Countries such as China, India, and Japan are at the forefront, with a high demand for both generic and innovative injectable drugs. In China, local manufacturing and foreign investment are extensive, catering to a vast domestic market. Japan is known for its technological advancements and invests heavily in pharmaceutical R&D, including next-generation injectable treatments. With a burgeoning pharmaceutical industry, India offers a large market for injectable drugs. Low-cost manufacturing and a growing middle class impact purchasing behaviors favorably toward more affordable injectable options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Injectable Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Injectable Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Cipla Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., Eli Lilly and Company, EVER Neuro Pharma GmbH, F. Hoffmann-La Roche Ltd., Ferring B.V., Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., SCHOTT PHARMA AG & CO. KGAA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecule Type
- Large Molecule
- Small Molecule

Drug Class
- Blood Factors
- Cytokines
- Immunoglobulin
- Insulin
- Monoclonal Antibodies
- Peptide Hormone

Injection Routes
- Intramuscular
- Intraocular
- Intrathecal
- Intravenous
- Subcutaneous

Application
- Autoimmune Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Oncology
- Pain

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Injectable Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Injectable Drugs Market?

3. What are the technology trends and regulatory frameworks in the Injectable Drugs Market?

4. What is the market share of the leading vendors in the Injectable Drugs Market?

5. Which modes and strategic moves are suitable for entering the Injectable Drugs Market?

Product Code: MRR-742BD517FCA4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Burden of Chronic Diseases
  - 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
  - 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
- 5.1.2. Restraints
  - 5.1.2.1. Rise in Incidences of Product Recall
- 5.1.3. Opportunities
  - 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
  - 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
- 5.1.4. Challenges
  - 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
5.2. Market Segmentation Analysis
- 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
- 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Injectable Drugs Market, by Molecule Type

6.1. Introduction
6.2. Large Molecule
6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

7.1. Introduction
7.2. Blood Factors
7.3. Cytokines
7.4. Immunoglobulin
7.5. Insulin
7.6. Monoclonal Antibodies
7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

8.1. Introduction
8.2. Intramuscular
8.3. Intraocular
8.4. Intrathecal
8.5. Intravenous
8.6. Subcutaneous

9. Injectable Drugs Market, by Application

9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cardiovascular Diseases
9.4. Infectious Diseases
9.5. Neurology
9.6. Oncology
9.7. Pain

10. Americas Injectable Drugs Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Injectable Drugs Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Sun Pharma and Taro announce merger agreement
- 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
- 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio